20:57:05 EDT Thu 20 Mar 2025
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

T:CSCI - COSCIENS BIOPHARMA INC - https://www.zentaris.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CSCI - T  0.54.60·5.030.14.63-1.35-22.615.7761685.75  5.75  4.6015.13  2.9016:10:00Mar 1915 min RT 2¢
TSX - T0.54.60·5.030.14.63-1.35-22.611.255725.75  5.75  4.6015.13  2.9016:10:0015 min
NEO ATS - U 5.05-0.93-15.61.47145.40  5.40  5.0112:12:2715 min
Pure - P 5.40-0.58-9.70.1115.40  5.40  5.4009:58:5115 min
Chi-X - X 5.40-0.58-9.70.1115.40  5.40  5.4009:58:5115 min
CXD - D 5.980.5241    Mar 1915 min
TriAct - M 5.981.1530    15 min
CS2 - S 5.06-0.92-15.41.2695.23  5.23  5.0111:06:0915 min

Recent Trades - Last 10 of 168
Time ETExPriceChangeVolumeBuyerSellerMarkers
16:10:00T4.63-1.351001 Anonymous1 AnonymousKQ
15:59:29D4.90-1.08507 TD Sec2 RBCE
15:56:07T4.88-1.1010079 CIBC80 National BankK
15:47:47T4.71-1.271007 TD Sec79 CIBCK
15:30:58T4.61-1.382980 National Bank124 Questrade
15:27:06T4.65-1.331007 TD Sec79 CIBCK
15:27:06T4.65-1.331007 TD Sec79 CIBCK
15:27:06T4.65-1.331007 TD Sec79 CIBCK
15:27:06T4.60-1.3810019 Desjardins79 CIBCK
15:27:06T4.66-1.3210079 CIBC79 CIBCK

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2025-03-19 19:19C:CSCI5.98News ReleaseCosciens Biopharma may delay filing 2024 financials
2025-03-13 16:43C:CSCI4.80News ReleaseCosciens starts phase 2a study on avenanthramides
2024-12-23 16:28C:CSCI3.72News ReleaseCosciens talks cost-cutting in 2024, focus for 2025
2024-11-12 08:03C:CSCI4.75SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-11-12 08:03C:CSCI4.75SEDAR Interim MD & ASEDAR Interim MD & A
2024-11-12 07:30C:CSCI4.75News ReleaseCOSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
2024-10-08 14:51C:CSCI5.05News ReleaseCosciens Biopharma director Egbert resigns
2024-10-01 19:51C:CSCI5.18News ReleaseCosciens Biopharma appoints Labbe to board
2024-09-23 15:13C:CSCI5.56News ReleaseCosciens begins seeking postmerger CEO, president
2024-08-27 13:08C:CSCI8.12News ReleaseCosciens's Detect trial did not meet primary end point
2024-08-13 08:16C:CSCI9.00SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-08-13 08:16C:CSCI9.00SEDAR Interim MD & ASEDAR Interim MD & A
2024-08-13 08:05C:CSCI9.00News ReleaseCOSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
2024-08-07 19:28C:CSCINew ListingAeterna Zentaris name change to Cosciens Biopharma
2024-08-07 19:28C:AEZS7.67Change NameAeterna Zentaris name change to Cosciens Biopharma
2024-08-06 19:09C:AEZS7.50News ReleaseAeterna Zentaris changes name to Cosciens Biopharma
2024-07-16 17:14C:AEZS8.28News ReleaseAeterna's Turpin fails to receive votes for re-election
2024-06-13 09:43C:AEZS9.09News ReleaseAeterna Zentaris completes phase 3 Detect trial
2024-06-03 09:35C:AEZS13.00News ReleaseAeterna Zentaris, Ceapro complete merger
2024-05-29 18:41C:AEZSNews ReleaseAeterna Zentaris applies for AGM date extension